Introduction
============

Prostate cancer (PCa) is the leading cause of cancer-related death in men in European and American countries [@B1]. The incidence and mortality of PCa in China are also on the increase in recent years and has become a major disease endangering the health of old men [@B2]. In addition to surgery and radiotherapy, androgen deprivation therapy (ADT) is the standard treatment for advanced PCa. However, most PCa patients may experience the transition from androgen-dependent prostate cancer (ADPC) to androgen-independent prostate cancer (AIPC) within 2-3 years after receiving ADT, resulting in an extremely high mortality rate [@B3], [@B4]. Therefore, the mechanism underling the occurrence of AIPC has long been a hot point of research, mainly involving amplification of the androgen receptor (AR) gene, mutation of AR, and abnormality of the apoptosis-regulatory gene [@B5]-[@B9].

In our previous study, we used ultra-performance liquid chromatography-electrospray ionization-quadrupole-time of flight mass spectrometry (UPLC-ESI-Q-TOF MS) and gas chromatography-mass spectrometry (GC-MS) to detect metabolic products after LNCaP cells underwent AIPC transition and discovered 23 potential differentially expressed metabolic products, including 13 phosphatidyl cholines (PC), 2 amides, 2 lysophosphatidylcholines (LPC), and a sphingomyelin (SM), a phosphatidyl ethanolamine (PE), a phytosphingosine, and other undefined compounds. Of them, PCs was abnormally increased by (1.22-7.69) fold after LNCaP cell transition to AIPC [@B10]. *Phospholipase D* (*PLD*) is an important enzyme that regulates phospholipid metabolism in the organism [@B11], [@B12]. In mammals, *PLD* exists in two forms: *PLD1* and *PLD*2 [@B13], [@B14]. Numerous studies have demonstrated that *PLD1* plays an important role in tumor occurrence, differentiation, apoptosis and metastasis [@B15], [@B16]. The aim of the present study was to determine whether *PLD1* also played an important role in PCa cell transition to AIPC.

Materials and Methods
=====================

Instruments and reagents
------------------------

The instruments and reagents used in this study were standard ADPC cell line LNCaP (Shanghai Cell Bank of the Chinese Academy of Sciences, Shanghai, China); F12, phenol red-free DMEM/F12, common fetal bovine serum (FBS) and charcoal stripped FBS (Gibco, USA); total RNA extraction reagent TRIzol (Invitrogen, USA); Revert Aid First Strand cDNA synthesis kit (Fermentas, Lithuania); ABI SYBR Green PCR Master Mix (ABI, USA); Arraystar Human LncRNA Microarray V3.0 (PT Solution Biotechnology CO., LTD., Shanghai, China); CCK-8 cell proliferation-toxicity test kit (Dojindo China Co., Ltd.); CO~2~ incubator (Thermo, USA); ABI 7500 real-time fluorescence quantitative PCR (ABI, USA).

Cell culture
------------

ADPC LNCaP cells were cultured in F12 containing 10% FBS. AIPC LNCaP-AI cells that had been successfully induced in our laboratory in our prior work were cultured in phenol red-free DMEM/F12 containing 10% fetal bovine serum (FBS) treated with activated carbon absorption in a 37°C 5% CO~2~ incubator. The medium was replaced 3-4 days after cell passaging, and about 7 days later confluent cells were digested with 0.25% trypsin for passage culture.

mRNA microarray
---------------

Total RNA was extracted from LNCaP and LNCaP-AI cells, the quality and quantity of which were verified by agarose gel electrophoresis. mRNA was isolated by using the mRNeasy Plus Mini Kit, labeled, hybridized, washed, and finally scanned with a laser confocal scanner. After quantile normalization and subsequent treatment of the original data by using GeneSpring GX v12.1 Software, mRNAs with more than 2-fold differential expression were screened out.

Verification of mRNA expression by quantitative real-time PCR
-------------------------------------------------------------

Cells were collected to extract total RNA, which was then reverse transcribed to cDNA. qPCR was performed by using cDNA (1μL) as the template and addition of 1.5μL upper- and down-stream primers (10μmol/L), 6μL RNase-free H~2~O and 10μL ABI SYBR Green PCR Master Mix, totaling 20μL under the condition of 95°C 15 min, 95°C 10 s, 58°C 40 s, totaling 40 cycles. The samples were stored at 4°C. Each sample was tested twice and the mean value was used for comparison. Using GAPDH as housekeeping gene of internal reference, the relative expression level of various target genes in LNCaP and LNCaP-AI cells, as well as the fold increase of the target genes in LNCaP-AI cells relative to LNCaP cells was calculated using the equation: ΔCt~(target\ gene)~=Ct~(target\ gene)~-Ct~(GAPDH\ of\ target\ cell)~, and ΔΔCt=ΔCt~(LNCaP-AI)~-ΔCt~(LNCaP)~.

Construction of the lentiviral vector and detection of cell proliferative activity by MTS assay
-----------------------------------------------------------------------------------------------

According to human *PLD1* mRNA (Accession: NM_002662), gene sequences were screened by software to design two specific shRNA interference sequences, to both ends of which appropriate restriction-enzyme cutting sites were added to complete the construction of the vector. In addition, a termination signal (TTTTT) was added to the positive 3\' end, and a termination signal compensatory sequence was added to the reverse 5\' end (Table [3](#T3){ref-type="table"}). Clones were cultured by connecting competent cells (DH5α) of product transformation, from which plasmids were extracted for enzyme digestion identification and sequencing, followed by transfection of 293T cells with Lipofectamine TM2000. The lentiviral RNA interference (RNAi) vector contained green fluorescence protein (GFP) in all groups. LNCaP-AI cells were infected with the lentivirus. Sequencing, viral packaging and titer determination were performed by Shanghai Genechem Co., Ltd (Shanghai, China). Knowing that the knockout efficiency of the PC positive targeted virus on the target gene is more than 70%; the target gene product plays an important role in the transcriptional process of mammalian cells; and silencing of this target gene can markedly inhibit cell proliferation in multiple tumor cell lines, it is often used as a positive reference in cell proliferation-related experiments to demonstrate the stability of the test system. Optical density was measured at 570nm (OD570) by MTS method in the positive control group, LNCaP-AI *PLD1* mRNA shRNAi group, and negative control group for 5 consecutive days to map out cell growth curves.

Data analysis
-------------

Statistical treatment was conducted by using SPSS 13.0. Measurement data were treated by independent-sample *t* test. Values of *P*\<0.05 were considered statistically significant.

Results
=======

Results of Arraystar Human LncRNA Microarray V3.0
-------------------------------------------------

Changes in mRNA differential expression in LNCaP cells before and after AIPC transition were analyzed by using Arraystar Human LncRNA Microarray V3.0 (containing 30,586 lncRNAs and 26,109 mRNAs). It was found that *PLD1* mRNA in LNCaP cells was increased after AIPC transition, and at the same time its downstream *Ras-PI3K-AKT* was activated and related molecule mRNA was increased markedly. We therefore used the result of RT-PCR to verify the reliability of the microarray result and found that the corresponding gene mRNAs were increased (Table [1](#T1){ref-type="table"}, 2 and Fig. [1](#F1){ref-type="fig"}), confirming that the results obtained from the two methods were consistent.

Impact of *PLD1* gene silencing on the proliferation of LNCaP-AI cells
----------------------------------------------------------------------

The knockout efficiency of the PC positive targeted virus on the target gene was more than 70%, confirming that the test system was stable. shCtrl refers to normal target cell^+^ negative control virus infection group; shPC refers to normal target cell^+^ positive gene shRNA virus infection group; shPLD*1* refers to normal target cell^+^ *PLD1* gene shRNA virus infection group (Table [3](#T3){ref-type="table"}, Fig. [2](#F2){ref-type="fig"}). OD570/fold refers to OD570 multiples during day 1-5 relative to day 1 in all groups, representing the daily fold change. The OD570/fold value at day 5 was used to judge fold change of cell proliferation in the shCtrl (negative control) group relative to the experimental group. Fold change≥1.2 means that the proliferation rate in the experimental group was slowed down as compared with the shCtrl group, based on which the RNAi lentivirus-specific target gene of the experimental group was judged as the proliferation-related positive gene.

The result of MTS showed that cell proliferation in the shCtrl group was normal and inhibited in the shPC group, indicating that the test system of the present study was normal. Fold change of cell proliferation in the shCtrl group versus the sh*PLD1* group was 1.3051 at day 5, indicating that the proliferation rate of LNCaP-AI cells was reduced by 30.51% after inhibition of the *PLD1* mRNA expression (Fig. [3](#F3){ref-type="fig"}).

Discussion
==========

Although numerous studies in recent years have demonstrated that *PLD* is closely associated with cell proliferation and tumor formation, and *PLD1* expression and activation were found to be up-regulated in multiple malignant tumors, the regulatory mechanism remains unclear [@B17]-[@B19]. In our prior work [@B20], we used natural ADPC cell line LNCaP as the control group and LNCaP-AI as the experiment group (induced by gradual tapering of the androgen concentration in the medium). When using UPLC-ESI-Q-TOF MS and GC-MS methods to detect the metabolic products after transition of LNCaP cells to AIPC, we accidentally found that PC was remarkably elevated. Knowing that *PLD* is an important enzyme participating in this metabolic process [@B10], we speculated that *PLD* might also participate in the process of AIPC transition.

In the present study, we used Arraystar Human LncRNA Microarray V3.0 to detect differential expression of *PLD1* mRNA and its signaling-related mRNA before and after LNCaP cells underwent AIPC transition. The results of the present microarray and our previous UPLC-ESI-Q-TOF MS/GC-MS showed that the PC level was elevated dramatically after LNCaP cell transition to AIPC, though the exact mechanism remains unclear; the expression of *PLD1* mRNA was up-regulated by 373 (373.44±75.80) fold; and the expression of the key molecule mRNA on its downstream *Ras-PI3K-AKT and mTOR* pathway was increased substantially (Fig [1](#F1){ref-type="fig"}), suggesting that in the androgen-free environment PCa cells could initiate some mechanism to increase the generation of the metabolic product PC, which in turn activated and increased the expression of its corresponding metabolic enzyme *PLD1* mRNA, thus promoting PC transition to phosphatidic acid (PA). PA is a second messenger that plays a central role in the important cancer-associated signaling pathway network, which further activates the downstream *Ras-PI3K-AKT and mTOR* pathway as represented by the increased mRNA expression of the key enzymes such as *PIK3R2, AKT3, C-raf* and *K-ras* [@B21], [@B22]. It was reported in the literature that *AKT* exerted its anti-apoptosis effect by phosphorylating the target protein via multiple downstream pathways [@B23], [@B24], and on the other hand the activated *AKT* regulated the cell function, proliferation and differentiation by phosphorylating multiple enzymes, kinases, transcription factors and other downstream factors[@B25], [@B26]. Therefore, activation of this pathway could partially explain why PCa cells can continue to survive in the androgen-free environment.

To observe the effect of *PLD1* mRNA expression on LNCaP cell proliferation after AIPC transition, we screened out two 19-21nt RNAi target sequences specific to *PLD1* mRNA in our subsequent experiment, based on which we designed a shRNAi sequence to construct a GV115 vector (GFP labeling) and encapsulated it into lentiviral particles to interfere with the expression of *PLD1* mRNA in LNCaP-AI cells. The results showed that the growth rate of LNCaP-AI cells that grew very fast in the androgen-free environment was decreased by 30% after *PLD1* mRNAi (Fig. [3](#F3){ref-type="fig"}), indicating that *PLD1* mRNA played a certain role in helping ADPC cells survive in the androgen-free environment. However, it is not the only factor affecting their survival, because interference only slowed down rather inhibited the rate of cell proliferation. In addition, the result of our microarrays showed that the expression of AR was up-regulated, suggesting PCa cells may continue to make use of the trace amount of androgen in the androgen-free environment to maintain their survival, or they may synthesize androgen intrinsically to maintain their viability [@B27]-[@B29].

In summary, our microarray and lentiviral interference have provided preliminary evidence that *PLD1* mRNA and related *PI3K/AKT and mTOR* signaling pathway may play important roles in the process of AIPC transition, although it may not be the only pathway. Down-regulating the *PLD1* mRNA expression could to some extent inhibit the proliferation rate of PCa cells after AIPC transition, which may provide a new way of thinking in clinical inhibition of PCa cell proliferation after AIPC transition.
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![The signaling pathway with *PLD1* participation was activated in LNCaP cells in the androgen-free environment.](jcav09p3620g001){#F1}

![Change in the growth rate of LNCaP-AI cells after lentiviral transfection. A. Evaluation of the lentivirus transduction rate, which was more than 80% as calculated by cellular enumeration using fluorescence and light microscopy, showing that the lentiviral vector stably expressing shRNA targeting *PLD1* was successfully constructed (×100). B. The cell growth state of LNCaP cells within 5 consecutive days after *PLD1* mRNA shRNA transfection (GFP labeling, ×10). sh*PLD1*: Fluorescence expression in the group transfected with *PLD1* mRNA shRNA lentivirus. shCtrl: Fluorescence expression in the negative control group. shPC: Fluorescence expression in the positive control group.](jcav09p3620g002){#F2}

![**MTS detection of OD570 changes in LNCaP-AI cells at different days after *PLD1* mRNAi.** The figure shows the cell proliferation curves in the three groups. The cell proliferation abilitywas assessed by the cell growth curve. sh*PLD1* delayed LNCaP-AI cell growth in the sh*PLD1* group in comparison with the shCtrl group.](jcav09p3620g003){#F3}

###### 

Sequences of gene primers including *PLD1* and *AKT3*

  Seq ID             Gene    Forward primer               Reverse primer
  ------------------ ------- ---------------------------- --------------------------
  **NM_001206729**   AKT3    GTTACCTTTCTACAACCAGGACCATG   GGTCCTCCACCAAGGCGTTTA
  **NM_000044**      AR      CGGCATGGTGAGCAGAGTGC         CAAAACATGGTCCCTGGCAGTC
  **NM_004322**      BAD     TTCCAGATCCCAGAGTTTGAGC       CCCATCCCTTCGTCGTCCT
  **NM_002880**      c-raf   CTTCTTTGACTATGCGTCGTATGC     GGGCTGAAGGTGAGGCTGATT
  **NM_004985**      K-ras   GTAGTTGGAGCTGGTGGCGTAG       CCTCATGTACTGGTCCCTCATTG
  **NM_004958**      mTOR    TTAGAGGACAGCGGGGAAGGC        GCAGGTCCGGTTCCAAGCATC
  **NM_005027**      PI3K    ACAGAGCGTGGGCTGGATG          ACTGCTCGGGCAAGTCGG
  **NM_001130081**   PLD1    GCCTATGGAAGGTGGGACGACA       CATTGCGGCAGGTGGGAGG
  **NM_003161**      S6K1    TGGACCAGCCAGAGGACGC          CCTTTACCAAGTACCCGAAGTAGC

###### 

Fold increase of gene mRNAs including PLD1 and AKT3 in LNCaP-AI relative to LNCaP group

  mRNA name   ΔCt(LNCaP)   ΔCt(LNCaP-AI)   ΔΔCt           fold increase   P
  ----------- ------------ --------------- -------------- --------------- --------
  *AKT3*      15.16±0.96   7.83±0.84       -(7.33±1.03)   182.43±120.37   0.0084
  *AR*        1.65±0.65    -(3.90±0.43)    -(5.55±0.11)   46.92±3.55      0.0046
  *BAD*       1.72±0.22    3.41±0.25       1.69±0.03      0.31±0.01       0.0195
  *C-raf*     8.27±0.27    5.76±0.14       -(2.51±0.57)   5.93±2.28       0.0156
  *K-ras*     7.09±0.09    3.24±0.12       -(3.84±0.02)   14.30±0.22      0.0011
  *mTOR*      0.48±0.17    -(0.56±0.26)    -(1.28±0.26)   2.43±0.84       0.0217
  *PI3K*      1.28±0.34    0.23±0.21       -(1.24±0.27)   2.04±0.22       0.0383
  *PLD1*      18.31±8.31   9.78±0.41       -(8.53±0.29)   373.44±75.80    0.0044
  *S6K1*      6.81±0.64    4.49±0.51       -(2.32±0.13)   5.00±0.91       0.0238

Note: ΔCt~(target\ gene)~=Ct~(target\ gene)~-Ct~(GAPDH\ of\ target\ cell)~, ΔΔCt=ΔCt~(LNCaP-AI)~-ΔCt~(LNCaP);~

Ct~(GAPDH\ of\ LNCaP)~=24.47±0.21, Ct~(GAPDH\ of\ LNCaP-AI)~=25.36±0.16.

###### 

Design of two shRNA sequences specific to human *PLD1*mRNA as the template

               5\' added base group   STEM                    Loop     STEM                    3\' added base group
  ------------ ---------------------- ----------------------- -------- ----------------------- ----------------------
  sequence 1                                                                                   
  a            CCGG                   AACTGGAAGATTACTTGACAA   CTCGAG   TTGTCAAGTAATCTTCCAGTT   TTTTTG
  b            AATTCAAAAA             AACTGGAAGATTACTTGACAA   CTCGAG   TTGTCAAGTAATCTTCCAGTT   
  sequence 2                                                                                   
  a            CCGG                   AAGAGGTGGCTGGTGGTGAAG   CTCGAG   CTTCACCACCAGCCACCTCTT   TTTTTG
  b            AATTCAAAAA             AAGAGGTGGCTGGTGGTGAAG   CTCGAG   CTTCACCACCAGCCACCTCTT   
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